Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics ( (AU:PER) ) has shared an update.
Percheron Therapeutics has notified the ASX of a proposed issue of up to 50 million unquoted options as part of a placement or similar capital initiative. The options will be exercisable at $0.01 per share and will expire two years from the date of issue, with an expected issue date of 15 April 2026.
The new options, which will constitute a separate class of unquoted securities, provide the company with an additional capital-raising and incentive mechanism for investors or stakeholders. This move may strengthen Percheron Therapeutics’ financial flexibility as it pursues its development activities and seeks to enhance its position in the biopharmaceutical sector.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an Australia-based biopharmaceutical company listed on the ASX under the code PER. The company focuses on developing therapeutic products, operating in the healthcare and life sciences sector with its securities traded on the Australian equities market.
Technical Sentiment Signal: Sell
Current Market Cap: A$6.52M
For an in-depth examination of PER stock, go to TipRanks’ Overview page.